At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 149 enrolled
Drug / intervention
LY3016859 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
In Brief
A Phase 2 clinical trial evaluating LY3016859 and Placebo for Chronic Low-back Pain. Completed, enrolled 149 participants across 34 sites in 2 countries.
Detailed Summary
This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Low-back Pain
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedAug 2020
Primary CompletionJun 2021
Study CompletionOct 2021
TodayJul 2026
First PostedAug 27, 2020
Enrollment StartAug 25, 2020
Primary CompletionJun 4, 2021
Study CompletionOct 4, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.8 years ago
Interventions
LY3016859drug
Administered IV
Placebodrug
Administered IV